This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Sulfate ion
- DrugBank Accession Number
- DB14546
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Sulfate ion (DB14546)
- Weight
- Average: 96.063
Monoisotopic: 95.951729178 - Chemical Formula
- O4S
- Synonyms
- Sulfate
- Sulfate dianion
- Sulfate(2-)
- Sulfuric acid ion(2-)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Sulfate ion. Aclidinium The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Sulfate ion is combined with Alloin. Almasilate The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Almasilate. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Loa Freedom S Capsule 100 g/1001 Oral LOA BIO INC. 2020-11-09 Not applicable US 
Loa New-freedom S Capsule 100 g/1001 Oral CO LTD JUNG MIN 2021-04-25 Not applicable US New-freedom S Capsule 100 g/1001 Oral CO LTD JUNG MIN 2021-04-25 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical Nano Bio Tech Co.,Ltd 2017-07-01 Not applicable US Telom-X-gene Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US VAMIN 14 IV AMINOASIT SOLÜSYONU, 500 ML Sulfate ion (8 mmol/L) + Acetate (135 mmol/L) + Alanine (12 g/L) + Arginine (8.4 g/L) + Aspartic acid (2.5 g/L) + Calcium (5 mmol/L) + Chloride ion (100 mmol/L) + Cysteine (420 mg/L) + Glutamic acid (4.2 g/L) + Glycine (5.9 g/L) + Histidine (5.1 g/L) + Isoleucine (4.2 g/L) + Leucine (5.9 g/L) + Lysine (6.8 g/L) + Magnesium (8 mmol/L) + Methionine (4.2 g/L) + Phenylalanine (5.9 g/L) + Potassium (50 mmol/L) + Proline (5.1 g/L) + Serine (3.4 g/L) + Sodium cation (100 mmol/L) + Threonine (4.2 g/L) + Tryptophan (1.4 g/L) + Tyrosine (170 mg/L) + Valine (5.5 g/L) Solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 2020-08-14 2019-10-12 Turkey 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Loa Freedom S Sulfate ion (100 g/1001) Capsule Oral LOA BIO INC. 2020-11-09 Not applicable US Loa New-freedom S Sulfate ion (100 g/1001) Capsule Oral CO LTD JUNG MIN 2021-04-25 Not applicable US New-freedom S Sulfate ion (100 g/1001) Capsule Oral CO LTD JUNG MIN 2021-04-25 Not applicable US Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical Nano Bio Tech Co.,Ltd 2017-07-01 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7IS9N8KPMG
- CAS number
- 14808-79-8
- InChI Key
- QAOWNCQODCNURD-UHFFFAOYSA-L
- InChI
- InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2
- IUPAC Name
- sulfate
- SMILES
- [O-]S([O-])(=O)=O
References
- General References
- Not Available
- External Links
- PDB Entries
- 101m / 102m / 103m / 104m / 105m / 106m / 107m / 108m / 109m / 110m … show 24752 more
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Diagnostic Cathartic Colon 1 4 Completed Treatment Inflammatory Bowel Diseases (IBD) / Iron Deficiency (ID) 1 4 Recruiting Prevention Anemia of Prematurity (AOP) / Very Low Birthweight Infants 1 4 Recruiting Treatment Chronic Kidney Disease (CKD) / Kidney Insufficiency, Chronic 1 4 Recruiting Treatment Fetal Alcohol Spectrum Disorders 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 100 g/1001 Liquid Topical Solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.84 Chemaxon pKa (Strongest Acidic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.53 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 103.6056324 predictedDarkChem Lite v0.1.0 [M-H]- 106.555504 predictedDeepCCS 1.0 (2019) [M-H]- 103.6056324 predictedDarkChem Lite v0.1.0 [M-H]- 106.555504 predictedDeepCCS 1.0 (2019) [M+H]+ 109.33417 predictedDeepCCS 1.0 (2019) [M+H]+ 109.33417 predictedDeepCCS 1.0 (2019) [M+Na]+ 117.68899 predictedDeepCCS 1.0 (2019) [M+Na]+ 117.68899 predictedDeepCCS 1.0 (2019)
Drug created at July 12, 2018 21:40 / Updated at June 12, 2020 16:53